<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640315</url>
  </required_header>
  <id_info>
    <org_study_id>12915</org_study_id>
    <secondary_id>2007-003919-31</secondary_id>
    <nct_id>NCT00640315</nct_id>
  </id_info>
  <brief_title>Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.</brief_title>
  <official_title>Proof of Concept Study to Investigate Safety, Tolerability, Pharmacokinetics and the Impact on Pulmonary and Systemic Hemodynamics, Gas Exchange and Lung Function Parameters of a Single-dose of BAY63-2521 IR-tablet in Patients With COPD Associated Pulmonary Hypertension in an Non-randomized, Non-blinded Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic
      effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to
      chronic obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to the pharmacodynamic and pharmacokinetic variables, the following laboratory
      variables were assessed:

        -  Hematology: Leucocytes, erythrocytes, hemoglobin, hematocrit, mean corpuscular volume
           (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration
           (MCHC), platelets, white blood cell (WBC), partial thromboplastin time (PTT),
           prothrombin time (Quick), international normalized ratio (INR) (prothrombin time
           expressed in relation to normal value) ;

        -  Clinical chemistry: aspartate aminotransferase (AST), alanine aminotransferase (ALT),
           alkaline phosphatase (AP), gamma glutamyl transpeptidase (GGT), creatine phosphokinase
           (CK), lipase, cholinesterase (CHE), glucose, creatinine, urea, uric acid, bilirubin,
           total protein, serum albumin, sodium, potassium, calcium, chloride.

      And due to the small number of subjects analyzed at several local labs, no summary statistics
      were provided.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Pulmonary Artery Pressure (PAPmean)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>PAPmean was reported during right heart catheterization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Vascular Resistance (PVR)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>PVR was calculated according to the formula PVR = 80*(PAPmean - pulmonary capillary wedge pressure)/cardiac output</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC) of Riociguat and Metabolite M1 After Single Dose of Riociguat</measure>
    <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D) of Riociguat and Metabolite M1 After Single Dose of Riociguat</measure>
    <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity Divided by Dose Per kg Body Weight (AUCnorm) of Riociguat and Metabolite M1 After Single Dose of Riociguat</measure>
    <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Drug Concentration in Plasma (Cmax) of Riociguat and Metabolite M1 After Single Dose of Riociguat</measure>
    <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Drug Concentration in Plasma Divided by Dose (Cmax/D) of Riociguat and Metabolite M1 After Single Dose of Riociguat</measure>
    <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Drug Concentration in Plasma Divided by Dose Per kg Body Weight (Cmax,Norm) of Riociguat and Metabolite M1 After Single Dose of Riociguat</measure>
    <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Right Atrial Pressure (RAPmean)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>RAPmean was reported during right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systolic Pulmonary Artery Pressure (PAPsyst)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>PAPsyst was acquired during right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Diastolic Pulmonary Artery Pressure (PAPdiast)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>PAPdiast was acquired during right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Capillary Wedge Pressure (PCWP)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>PCWP was acquired during right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Heart Rate (HR)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>HR was acquired during right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systolic Blood Pressure (SBP)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>Systolic arterial blood pressure was acquired during right heart catheterization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Diastolic Blood Pressure (DBP)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>Diastolic arterial blood pressure was acquired during right heart catheterization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Arterial Pressure (MAP)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>MAP was acquired during right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Cardiac Output (CO)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>CO was measured in triplicate by the thermodilution technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Vascular Resistance Index (PVRI)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>PVRI was calculated as PVRI = (80*(PAPmean - PCWP)/CO)*body surface area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systemic Vascular Resistance (SVR)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>SVR was calculated as SVR = 80*(MAP-RAPmean)/CO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systemic Vascular Resistance Index (SVRI)</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>SVRI was calculated as SVRI = (80*(MAP - RAPmean)/CO)*body surface area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Cardiac Index</measure>
    <time_frame>From baseline up to 4 hours after administration</time_frame>
    <description>Cardiac index was calculated as cardiac index = CO / body surface area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Partial Oxygen Pressure (PaO2)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
    <description>Arterial blood gas analysis was performed by insertion of an indwelling arterial cannula. Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Partial Pressure of Carbon Dioxide (PaCO2)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
    <description>Arterial blood gas analysis was performed by insertion of an indwelling arterial cannula. Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Venous Oxygen Pressure (PvO2)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
    <description>Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Oxygen Saturation (SaO2)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
    <description>Arterial blood gas analysis was performed by insertion of an indwelling arterial cannula. Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Venous Oxygen Saturation (SvO2)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
    <description>Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted FEV1</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted FVC</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of FEV1/FVC</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Lung Capacity (TLC)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted TLC</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
    <description>The percent of predicted TLC was provided by investigator at site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Residual Volume (RV)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted RV</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 75% of Expiratory Vital Capacity (MEF75)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 50% of Expiratory Vital Capacity (MEF50)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 25% of Expiratory Vital Capacity (MEF25)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Airway Resistance (Raw)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Vital Capacity (VC)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted VC</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Lung Capacity at the Time When the DLCO is Measured (Alveolar Volume, VA)</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Specific Diffusing Capacity</measure>
    <time_frame>Baseline and 2 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Total Ventilation (V)</measure>
    <time_frame>Baseline and 1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Total Perfusion (Q)</measure>
    <time_frame>Baseline and 1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Dead Space Ventilation</measure>
    <time_frame>Baseline and 1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Low V/Q Perfusion</measure>
    <time_frame>Baseline and 1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Normal V/Q Perfusion</measure>
    <time_frame>Baseline and 1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hours Post Dose of Ventilation-perfusion Distribution Presented as Standard Deviation (SD) of Perfusion</measure>
    <time_frame>Baseline and 1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Ventilation-perfusion Distribution Presented as Standard Deviation (SD) of Ventilation</measure>
    <time_frame>Baseline and 1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Intrapulmonary Shunt Flow</measure>
    <time_frame>Baseline and 1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Drug Concentration in Plasma (Tmax) of Riociguat and Metabolite M1 After Single Dose of Riociguat</measure>
    <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With the Terminal Slope (t1/2) of Riociguat and Metabolite M1 After Single Dose of Riociguat</measure>
    <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT) of Riociguat and Metabolite M1 After Single Dose of Riociguat</measure>
    <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Verse Time Curve From Zero to the Last Data Point (AUC0-tn) of Riociguat and Metabolite M1 After Single Dose of Riociguat</measure>
    <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean PR Duration (PRmean) - Change From Baseline to Day 3</measure>
    <time_frame>Baseline and day 3</time_frame>
    <description>PR duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean QRS Duration (QRSmean) - Change From Baseline to Day 3</measure>
    <time_frame>Baseline and day 3</time_frame>
    <description>QRS duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean QT Duration (QTmean) - Change From Baseline to Day 3</measure>
    <time_frame>Baseline and day 3</time_frame>
    <description>QT duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean QTcB Duration (Bazett's Correction Formula, QTcB) - Change From Baseline to Day 3</measure>
    <time_frame>Baseline and day 3</time_frame>
    <description>Bazett-corrected QTcB duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean QTcF Duration (Fridericia's Correction Formula, QTcF) - Change From Baseline to Day 3</measure>
    <time_frame>Baseline and day 3</time_frame>
    <description>Fridericia-corrected QTcF duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Riociguat (Adempas, BAY63-2521) 1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riociguat (Adempas, BAY63-2521) 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521) 1.0 mg</intervention_name>
    <description>1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).</description>
    <arm_group_label>Riociguat (Adempas, BAY63-2521) 1.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521) 2.5 mg</intervention_name>
    <description>2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).</description>
    <arm_group_label>Riociguat (Adempas, BAY63-2521) 2.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pulmonary hypertension due to COPD, undergoing routine invasive
             measurement of hemodynamic parameters.

          -  Catheters for measurement of hemodynamic parameters (PAP [pulmonary artery pressure],
             PCWP [pulmonary capillary wedge pressure], CO [cardiac output], SBP [systolic blood
             pressure]) must be in place independent of the trial.

        Exclusion Criteria:

          -  Acute exacerbation of COPD,

          -  Pre-existing lung disease other than COPD,

          -  Acute or severe chronic left heart failure,

          -  Severe coronary artery disease,

          -  Uncontrolled arterial hypertension;

          -  Severe left ventricular hypertrophy,

          -  Congenital or acquired valvular or myocardial disease,

          -  Systolic blood pressure &lt; 100 mmHg,

          -  Heart rate &lt; 55 bpm or &gt;105 bpm,

          -  PaO2 (arterial partial oxygen pressure)/FiO2 (fraction of inspired oxygen) &lt; 50 mmHg,

          -  PaCO2 (arterial partial pressure of carbon dioxide) &gt; 55 mmHg,

          -  Severe hepatic insufficiency,

          -  Severe renal insufficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Löwenstein</city>
        <state>Baden-Württemberg</state>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <results_reference>
    <citation>H.-A. Ghofrani, G. Staehler, E. Gruenig, M. Halank, V. Mitrovic, S. Unger, W. Mueck, R. Frey, J. Behr. The Effect Of The Soluble Guanylate Cyclase Stimulator Riociguat On Hemodynamics In Patients With Pulmonary Hypertension Due To Chronic Obstructive Pulmonary Disease. D96 CLINICAL TRIALS AND OUTCOMES IN PULMONARY HYPERTENSION.</citation>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <results_first_submitted>November 7, 2013</results_first_submitted>
  <results_first_submitted_qc>January 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2014</results_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Pulmonary hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
          <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
        </group>
        <group group_id="P2">
          <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
          <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
          <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
        </group>
        <group group_id="B2">
          <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
          <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="8.9" lower_limit="56" upper_limit="82"/>
                    <measurement group_id="B2" value="69.2" spread="5.7" lower_limit="61" upper_limit="79"/>
                    <measurement group_id="B3" value="68.4" spread="7.1" lower_limit="56" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Pulmonary Artery Pressure (PAPmean)</title>
        <description>PAPmean was reported during right heart catheterization</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Pulmonary Artery Pressure (PAPmean)</title>
          <description>PAPmean was reported during right heart catheterization</description>
          <population>per-protocol population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.60" spread="3.41"/>
                    <measurement group_id="O2" value="-4.83" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Vascular Resistance (PVR)</title>
        <description>PVR was calculated according to the formula PVR = 80*(PAPmean - pulmonary capillary wedge pressure)/cardiac output</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Vascular Resistance (PVR)</title>
          <description>PVR was calculated according to the formula PVR = 80*(PAPmean - pulmonary capillary wedge pressure)/cardiac output</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>(dyn*s*cm^-5)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.32" spread="50.46"/>
                    <measurement group_id="O2" value="-123.8" spread="73.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
        <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
          <population>per-protocol population</population>
          <units>µg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Riociguat - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481.9" spread="65.3"/>
                    <measurement group_id="O2" value="1319" spread="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Riociguat - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="605.5" spread="79.1"/>
                    <measurement group_id="O2" value="999.5" spread="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient number of participants with data.</measurement>
                    <measurement group_id="O2" value="1019" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient number of participants with data.</measurement>
                    <measurement group_id="O2" value="NA">Insufficient number of participants with data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
        <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
          <population>per-protocol population</population>
          <units>10^3*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Riociguat - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481.9" spread="65.3"/>
                    <measurement group_id="O2" value="527.4" spread="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Riociguat - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="605.5" spread="79.1"/>
                    <measurement group_id="O2" value="399.8" spread="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient number of participants with data.</measurement>
                    <measurement group_id="O2" value="421.6" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient number of participants with data.</measurement>
                    <measurement group_id="O2" value="NA">Insufficient number of participants with data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity Divided by Dose Per kg Body Weight (AUCnorm) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
        <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity Divided by Dose Per kg Body Weight (AUCnorm) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
          <population>per-protocol population</population>
          <units>kg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Riociguat - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.53" spread="62.6"/>
                    <measurement group_id="O2" value="38.85" spread="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Riociguat - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.86" spread="68.0"/>
                    <measurement group_id="O2" value="29.93" spread="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient number of participants with data.</measurement>
                    <measurement group_id="O2" value="31.03" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient number of participants with data.</measurement>
                    <measurement group_id="O2" value="NA">Insufficient number of participants with data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Drug Concentration in Plasma (Cmax) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
        <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Drug Concentration in Plasma (Cmax) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
          <population>per-protocol population</population>
          <units>µg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Riociguat - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.96" spread="32.3"/>
                    <measurement group_id="O2" value="116.0" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Riociguat - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.30" spread="46.0"/>
                    <measurement group_id="O2" value="80.44" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.44" spread="56.5"/>
                    <measurement group_id="O2" value="27.27" spread="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.869" spread="37.2"/>
                    <measurement group_id="O2" value="26.49" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Drug Concentration in Plasma Divided by Dose (Cmax/D) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
        <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Drug Concentration in Plasma Divided by Dose (Cmax/D) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
          <population>per-protocol population</population>
          <units>10^3/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Riociguat - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.96" spread="32.3"/>
                    <measurement group_id="O2" value="46.42" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Riociguat - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.30" spread="46.0"/>
                    <measurement group_id="O2" value="32.18" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.80" spread="56.5"/>
                    <measurement group_id="O2" value="11.28" spread="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.21" spread="37.2"/>
                    <measurement group_id="O2" value="10.96" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Drug Concentration in Plasma Divided by Dose Per kg Body Weight (Cmax,Norm) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
        <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Drug Concentration in Plasma Divided by Dose Per kg Body Weight (Cmax,Norm) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
          <population>per-protocol population</population>
          <units>kg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Riociguat - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.185" spread="27.0"/>
                    <measurement group_id="O2" value="3.419" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Riociguat - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.617" spread="39.1"/>
                    <measurement group_id="O2" value="2.370" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.800" spread="46.8"/>
                    <measurement group_id="O2" value="0.831" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.757" spread="26.8"/>
                    <measurement group_id="O2" value="0.807" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Right Atrial Pressure (RAPmean)</title>
        <description>RAPmean was reported during right heart catheterization</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Right Atrial Pressure (RAPmean)</title>
          <description>RAPmean was reported during right heart catheterization</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="1.41"/>
                    <measurement group_id="O2" value="-0.64" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systolic Pulmonary Artery Pressure (PAPsyst)</title>
        <description>PAPsyst was acquired during right heart catheterization</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systolic Pulmonary Artery Pressure (PAPsyst)</title>
          <description>PAPsyst was acquired during right heart catheterization</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.90" spread="4.86"/>
                    <measurement group_id="O2" value="-9.42" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Diastolic Pulmonary Artery Pressure (PAPdiast)</title>
        <description>PAPdiast was acquired during right heart catheterization</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Diastolic Pulmonary Artery Pressure (PAPdiast)</title>
          <description>PAPdiast was acquired during right heart catheterization</description>
          <population>per-protocol population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.80" spread="4.73"/>
                    <measurement group_id="O2" value="-3.25" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Capillary Wedge Pressure (PCWP)</title>
        <description>PCWP was acquired during right heart catheterization</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Capillary Wedge Pressure (PCWP)</title>
          <description>PCWP was acquired during right heart catheterization</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.60" spread="3.57"/>
                    <measurement group_id="O2" value="-1.17" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Heart Rate (HR)</title>
        <description>HR was acquired during right heart catheterization</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Heart Rate (HR)</title>
          <description>HR was acquired during right heart catheterization</description>
          <population>per-protocol population</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" spread="7.31"/>
                    <measurement group_id="O2" value="13.92" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systolic Blood Pressure (SBP)</title>
        <description>Systolic arterial blood pressure was acquired during right heart catheterization.</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systolic Blood Pressure (SBP)</title>
          <description>Systolic arterial blood pressure was acquired during right heart catheterization.</description>
          <population>per-protocol population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.30" spread="16.63"/>
                    <measurement group_id="O2" value="-22.17" spread="15.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Diastolic Blood Pressure (DBP)</title>
        <description>Diastolic arterial blood pressure was acquired during right heart catheterization.</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Diastolic Blood Pressure (DBP)</title>
          <description>Diastolic arterial blood pressure was acquired during right heart catheterization.</description>
          <population>per-protocol population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.50" spread="6.84"/>
                    <measurement group_id="O2" value="-11.25" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Arterial Pressure (MAP)</title>
        <description>MAP was acquired during right heart catheterization</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Mean Arterial Pressure (MAP)</title>
          <description>MAP was acquired during right heart catheterization</description>
          <population>per-protocol population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.10" spread="7.71"/>
                    <measurement group_id="O2" value="-13.92" spread="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Cardiac Output (CO)</title>
        <description>CO was measured in triplicate by the thermodilution technique</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Cardiac Output (CO)</title>
          <description>CO was measured in triplicate by the thermodilution technique</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.48"/>
                    <measurement group_id="O2" value="1.61" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Vascular Resistance Index (PVRI)</title>
        <description>PVRI was calculated as PVRI = (80*(PAPmean - PCWP)/CO)*body surface area</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Pulmonary Vascular Resistance Index (PVRI)</title>
          <description>PVRI was calculated as PVRI = (80*(PAPmean - PCWP)/CO)*body surface area</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>dyn*s*cm^-5*m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-108.6" spread="93.46"/>
                    <measurement group_id="O2" value="-222.1" spread="130.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systemic Vascular Resistance (SVR)</title>
        <description>SVR was calculated as SVR = 80*(MAP-RAPmean)/CO</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systemic Vascular Resistance (SVR)</title>
          <description>SVR was calculated as SVR = 80*(MAP-RAPmean)/CO</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>dyn*s*cm^-5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-440.0" spread="205.78"/>
                    <measurement group_id="O2" value="-467.7" spread="154.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systemic Vascular Resistance Index (SVRI)</title>
        <description>SVRI was calculated as SVRI = (80*(MAP - RAPmean)/CO)*body surface area</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Systemic Vascular Resistance Index (SVRI)</title>
          <description>SVRI was calculated as SVRI = (80*(MAP - RAPmean)/CO)*body surface area</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>dyn*s*cm^-5*m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-836.4" spread="385.92"/>
                    <measurement group_id="O2" value="-837.9" spread="276.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Cardiac Index</title>
        <description>Cardiac index was calculated as cardiac index = CO / body surface area.</description>
        <time_frame>From baseline up to 4 hours after administration</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Swan-Ganz Hemodynamics - Maximal Change From Baseline at Day 1 of Cardiac Index</title>
          <description>Cardiac index was calculated as cardiac index = CO / body surface area.</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>L/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.26"/>
                    <measurement group_id="O2" value="0.89" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Partial Oxygen Pressure (PaO2)</title>
        <description>Arterial blood gas analysis was performed by insertion of an indwelling arterial cannula. Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Partial Oxygen Pressure (PaO2)</title>
          <description>Arterial blood gas analysis was performed by insertion of an indwelling arterial cannula. Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.64" spread="24.79"/>
                    <measurement group_id="O2" value="-12.99" spread="14.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Partial Pressure of Carbon Dioxide (PaCO2)</title>
        <description>Arterial blood gas analysis was performed by insertion of an indwelling arterial cannula. Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Partial Pressure of Carbon Dioxide (PaCO2)</title>
          <description>Arterial blood gas analysis was performed by insertion of an indwelling arterial cannula. Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.43" spread="20.93"/>
                    <measurement group_id="O2" value="4.04" spread="13.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Venous Oxygen Pressure (PvO2)</title>
        <description>Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Venous Oxygen Pressure (PvO2)</title>
          <description>Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="8.57"/>
                    <measurement group_id="O2" value="12.07" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Oxygen Saturation (SaO2)</title>
        <description>Arterial blood gas analysis was performed by insertion of an indwelling arterial cannula. Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Arterial Oxygen Saturation (SaO2)</title>
          <description>Arterial blood gas analysis was performed by insertion of an indwelling arterial cannula. Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="3.89"/>
                    <measurement group_id="O2" value="-2.89" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Venous Oxygen Saturation (SvO2)</title>
        <description>Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Gas Analysis - Percentage Change From Baseline at 2 Hours Post Dose of Venous Oxygen Saturation (SvO2)</title>
          <description>Percent change was calculated as &quot;100%*(value post dose - value at baseline)/ value at baseline&quot;.</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="6.58"/>
                    <measurement group_id="O2" value="6.76" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Forced Expiratory Volume in 1 Second (FEV1)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Forced Expiratory Volume in 1 Second (FEV1)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="3.32"/>
                    <measurement group_id="O2" value="3.81" spread="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted FEV1</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted FEV1</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="3.38"/>
                    <measurement group_id="O2" value="4.35" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Forced Vital Capacity (FVC)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Forced Vital Capacity (FVC)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.16" spread="16.08"/>
                    <measurement group_id="O2" value="8.62" spread="23.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted FVC</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted FVC</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="8.01"/>
                    <measurement group_id="O2" value="8.65" spread="23.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of FEV1/FVC</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of FEV1/FVC</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="11.26"/>
                    <measurement group_id="O2" value="-1.29" spread="17.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Lung Capacity (TLC)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Lung Capacity (TLC)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="10.53"/>
                    <measurement group_id="O2" value="2.14" spread="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted TLC</title>
        <description>The percent of predicted TLC was provided by investigator at site.</description>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted TLC</title>
          <description>The percent of predicted TLC was provided by investigator at site.</description>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="10.63"/>
                    <measurement group_id="O2" value="2.08" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Residual Volume (RV)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Residual Volume (RV)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="9.15"/>
                    <measurement group_id="O2" value="3.16" spread="22.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted RV</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted RV</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="9.09"/>
                    <measurement group_id="O2" value="3.21" spread="22.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 75% of Expiratory Vital Capacity (MEF75)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 75% of Expiratory Vital Capacity (MEF75)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="22.28"/>
                    <measurement group_id="O2" value="-1.09" spread="17.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 50% of Expiratory Vital Capacity (MEF50)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 50% of Expiratory Vital Capacity (MEF50)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="18.29"/>
                    <measurement group_id="O2" value="5.59" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 25% of Expiratory Vital Capacity (MEF25)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Maximal Expiratory Flow at 25% of Expiratory Vital Capacity (MEF25)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.56" spread="29.57"/>
                    <measurement group_id="O2" value="-0.61" spread="40.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Airway Resistance (Raw)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Airway Resistance (Raw)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.78" spread="24.03"/>
                    <measurement group_id="O2" value="-5.89" spread="34.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Vital Capacity (VC)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Vital Capacity (VC)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.55" spread="22.35"/>
                    <measurement group_id="O2" value="10.09" spread="20.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted VC</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Percent of Predicted VC</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.60" spread="22.89"/>
                    <measurement group_id="O2" value="10.00" spread="20.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.67" spread="26.65"/>
                    <measurement group_id="O2" value="18.66" spread="17.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Lung Capacity at the Time When the DLCO is Measured (Alveolar Volume, VA)</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Total Lung Capacity at the Time When the DLCO is Measured (Alveolar Volume, VA)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="6.90"/>
                    <measurement group_id="O2" value="1.72" spread="12.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Specific Diffusing Capacity</title>
        <time_frame>Baseline and 2 hours post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Percentage Change From Baseline at 2 Hours Post Dose of Specific Diffusing Capacity</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.77" spread="27.36"/>
                    <measurement group_id="O2" value="18.61" spread="16.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Total Ventilation (V)</title>
        <time_frame>Baseline and 1 hour post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Total Ventilation (V)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="1.00"/>
                    <measurement group_id="O2" value="-0.10" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Total Perfusion (Q)</title>
        <time_frame>Baseline and 1 hour post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Total Perfusion (Q)</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.50"/>
                    <measurement group_id="O2" value="-0.40" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Dead Space Ventilation</title>
        <time_frame>Baseline and 1 hour post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Dead Space Ventilation</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage of total ventilation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="8.50"/>
                    <measurement group_id="O2" value="-42.50">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Low V/Q Perfusion</title>
        <time_frame>Baseline and 1 hour post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Low V/Q Perfusion</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="13.40"/>
                    <measurement group_id="O2" value="-0.30">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Normal V/Q Perfusion</title>
        <time_frame>Baseline and 1 hour post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Normal V/Q Perfusion</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.80" spread="21.00"/>
                    <measurement group_id="O2" value="4.10">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hours Post Dose of Ventilation-perfusion Distribution Presented as Standard Deviation (SD) of Perfusion</title>
        <time_frame>Baseline and 1 hour post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hours Post Dose of Ventilation-perfusion Distribution Presented as Standard Deviation (SD) of Perfusion</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>L/MIN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.10"/>
                    <measurement group_id="O2" value="-0.10">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Ventilation-perfusion Distribution Presented as Standard Deviation (SD) of Ventilation</title>
        <time_frame>Baseline and 1 hour post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Ventilation-perfusion Distribution Presented as Standard Deviation (SD) of Ventilation</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>L/MIN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.40"/>
                    <measurement group_id="O2" value="-0.50">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Intrapulmonary Shunt Flow</title>
        <time_frame>Baseline and 1 hour post dose</time_frame>
        <population>per-protocol population (subjects with data available for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Inert Gas Elimination Technique (MIGET) Analysis - Change From Baseline at 1 Hour Post Dose of Intrapulmonary Shunt Flow</title>
          <population>per-protocol population (subjects with data available for this outcome measure)</population>
          <units>Percentage of total perfusion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="1.70"/>
                    <measurement group_id="O2" value="-0.30">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Drug Concentration in Plasma (Tmax) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
        <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Drug Concentration in Plasma (Tmax) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
          <population>per-protocol population</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Riociguat - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="0.917" upper_limit="4"/>
                    <measurement group_id="O2" value="1.742" lower_limit="1" upper_limit="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Riociguat - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.033" lower_limit="2" upper_limit="5.917"/>
                    <measurement group_id="O2" value="2.042" lower_limit="1.867" upper_limit="24.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.97" lower_limit="4" upper_limit="36.25"/>
                    <measurement group_id="O2" value="10.04" lower_limit="3" upper_limit="24.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.017" lower_limit="2.15" upper_limit="24.42"/>
                    <measurement group_id="O2" value="12.04" lower_limit="2" upper_limit="24.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life Associated With the Terminal Slope (t1/2) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
        <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life Associated With the Terminal Slope (t1/2) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
          <population>per-protocol population</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Riociguat - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.422" spread="58.6"/>
                    <measurement group_id="O2" value="9.541" spread="50.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Riociguat - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.18" spread="47.5"/>
                    <measurement group_id="O2" value="8.835" spread="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient number of participants with data.</measurement>
                    <measurement group_id="O2" value="20.57" spread="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient number of participants with data.</measurement>
                    <measurement group_id="O2" value="NA">Insufficient number of participants with data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
        <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
          <population>per-protocol population</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Riociguat - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.92" spread="50.2"/>
                    <measurement group_id="O2" value="13.97" spread="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Riociguat - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.88" spread="39.5"/>
                    <measurement group_id="O2" value="13.37" spread="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient number of participants with data.</measurement>
                    <measurement group_id="O2" value="34.77" spread="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient number of participants with data.</measurement>
                    <measurement group_id="O2" value="NA">Insufficient number of participants with data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Verse Time Curve From Zero to the Last Data Point (AUC0-tn) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
        <time_frame>Study day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36 hours post-dose; Study day 3: 0, 2, 6, 12, 24 hours post-dose</time_frame>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Verse Time Curve From Zero to the Last Data Point (AUC0-tn) of Riociguat and Metabolite M1 After Single Dose of Riociguat</title>
          <population>per-protocol population</population>
          <units>µg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Riociguat - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426.3" spread="66.1"/>
                    <measurement group_id="O2" value="1196" spread="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Riociguat - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.7" spread="81.6"/>
                    <measurement group_id="O2" value="750.3" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 1 (00d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.1" spread="76.6"/>
                    <measurement group_id="O2" value="727.4" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M1 - Study day 3 (02d01h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.4" spread="98.8"/>
                    <measurement group_id="O2" value="490.6" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean PR Duration (PRmean) - Change From Baseline to Day 3</title>
        <description>PR duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
        <time_frame>Baseline and day 3</time_frame>
        <population>All subjects who received at least one dose of the trial medication were included in the safety evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PR Duration (PRmean) - Change From Baseline to Day 3</title>
          <description>PR duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
          <population>All subjects who received at least one dose of the trial medication were included in the safety evaluation.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="21.60"/>
                    <measurement group_id="O2" value="11.20" spread="27.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean QRS Duration (QRSmean) - Change From Baseline to Day 3</title>
        <description>QRS duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
        <time_frame>Baseline and day 3</time_frame>
        <population>All subjects who received at least one dose of the trial medication were included in the safety evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean QRS Duration (QRSmean) - Change From Baseline to Day 3</title>
          <description>QRS duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
          <population>All subjects who received at least one dose of the trial medication were included in the safety evaluation.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" spread="5.79"/>
                    <measurement group_id="O2" value="0.68" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean QT Duration (QTmean) - Change From Baseline to Day 3</title>
        <description>QT duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
        <time_frame>Baseline and day 3</time_frame>
        <population>All subjects who received at least one dose of the trial medication were included in the safety evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean QT Duration (QTmean) - Change From Baseline to Day 3</title>
          <description>QT duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
          <population>All subjects who received at least one dose of the trial medication were included in the safety evaluation.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="22.03"/>
                    <measurement group_id="O2" value="-36.88" spread="15.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean QTcB Duration (Bazett's Correction Formula, QTcB) - Change From Baseline to Day 3</title>
        <description>Bazett-corrected QTcB duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
        <time_frame>Baseline and day 3</time_frame>
        <population>All subjects who received at least one dose of the trial medication were included in the safety evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean QTcB Duration (Bazett's Correction Formula, QTcB) - Change From Baseline to Day 3</title>
          <description>Bazett-corrected QTcB duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
          <population>All subjects who received at least one dose of the trial medication were included in the safety evaluation.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="23.08"/>
                    <measurement group_id="O2" value="0.95" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean QTcF Duration (Fridericia's Correction Formula, QTcF) - Change From Baseline to Day 3</title>
        <description>Fridericia-corrected QTcF duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
        <time_frame>Baseline and day 3</time_frame>
        <population>All subjects who received at least one dose of the trial medication were included in the safety evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
            <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
          </group>
          <group group_id="O2">
            <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
            <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean QTcF Duration (Fridericia's Correction Formula, QTcF) - Change From Baseline to Day 3</title>
          <description>Fridericia-corrected QTcF duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position.</description>
          <population>All subjects who received at least one dose of the trial medication were included in the safety evaluation.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="20.15"/>
                    <measurement group_id="O2" value="-12.73" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected after signing the informed consent until 30 days after end of study treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Riociguat (Adempas, BAY63-2521) 1.0 mg</title>
          <description>Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.</description>
        </group>
        <group group_id="E2">
          <title>Riociguat (Adempas, BAY63-2521) 2.5 mg</title>
          <description>Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator may prepare the data derived from the Trial for publication. Such data will be submitted to the Sponsor for review at least 60 days prior to submission for publication. The Sponsor should respond within 50 days after receipt of the manuscript. The Investigator agrees that all reasonable comments made by the Sponsor in relation to a proposed publication will be incorporated. Confidential data provided by the Sponsor may not be published without written approval of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

